A Summary of a NAD⁺ and Aging Clinical Study by Yang et al. (2022)

Reviewed by John Cutts, PhD | Research & Development

Overview

The following summary reviews a cross-sectional clinical study examining the association between whole blood NAD⁺ concentrations and chronological age and whether gender modifies this relationship.

Summary

Association of Human Whole Blood NAD⁺ Contents With Aging

Published in: Frontiers in Endocrinology

Study Design: Cross-sectional observational study

Participants: 1,518 adults aged 18 years and older (mean age 43.0 years; 52.6% male) recruited from the Jidong community in Tangshan, China; individuals with cardiovascular disease, any cancer history, or abnormal NAD⁺ values were excluded

Dose: Not applicable (no intervention administered; this was an observational study)

Outcome Measures: Whole blood NAD⁺ concentration measured by enzymatic cycling assay and LC–MS/MS; general linear regression models with β coefficients and 95% confidence intervals; gender-stratified subgroup analysis

What Was Studied: Researchers investigated whether whole blood NAD⁺ levels are associated with chronological aging in a large community-based population and whether this association differs by gender. Participants were divided into five age groups (≤29, 30–39, 40–49, 50–59, and ≥60 years), and whole blood NAD⁺ was measured. Linear regression models were used to assess the association between NAD⁺ concentrations and age group, with adjustments for BMI, smoking, alcohol consumption, dietary patterns, clinical comorbidities, and red blood cell count.

About the Reviewer

Name & Title: John Cutts, Director of Research at Solaray
Credentials: PhD Pharmacology & Toxicology

Bio: John Cutts, Ph.D. earned his Doctorate of Philosophy in Pharmacology and Toxicology from the University of Alabama at Birmingham and his Bachelors of Science in Chemistry from BYU-Idaho. He has nearly 20 years of experience in the dietary supplement space, with a focus on scientific substantiation, regulatory affairs, and product development. His graduate research centered on the health-related properties of botanical compounds. He currently works in research and development, where he evaluates clinical evidence for dietary supplement ingredients.

Reference

Yang F, Deng X, Yu Y, Luo L, Chen X, Zheng J, Qiu Y, Xiao F, Xie X, Zhao Y, Guo J, Hu F, Zhang X, Ju Z, Zhou Y. (2022). Association of Human Whole Blood NAD⁺ Contents With Aging. Frontiers in Endocrinology, 13, 829658. https://pubmed.ncbi.nlm.nih.gov/35388296/

Back to blog

Frequently Asked Questions

What makes a study “double-blind”?

In double-blind studies, participants and researchers are
both unaware of which participants are in the group taking the active
investigational product and which are part of a control group.

What makes a study “placebo-controlled”?

When studies are placebo-controlled one group takes an active
investigational product and the other group takes an inactive product that has
the same general appearances as the active treatment.

What is a placebo?

Placebos are inactive treatments. Researchers include placebos that have the same general characteristics as an active treatment.

They try to make them indistinguishable from the active treatment regarding
qualities like appearance, taste, and smell.

Why is statistical significance important?

Quality scientific studies look for more than just a numerical difference between treated groups and control groups. These studies also check mathematically for the possibility that any difference between groups might
happen by chance. A difference that is statistically significant is one where the change is not likely to be due to a chance fluctuation within a normal variance.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.